Form 8-K - Current report:
SEC Accession No. 0001493152-26-001959
Filing Date
2026-01-13
Accepted
2026-01-13 08:35:24
Documents
15
Period of Report
2026-01-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 46116
2 EX-99.1 ex99-1.htm EX-99.1 17706
3 GRAPHIC ex99-1_001.jpg GRAPHIC 7722
  Complete submission text file 0001493152-26-001959.txt   294187

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bfri-20260113.xsd EX-101.SCH 3966
5 XBRL DEFINITION FILE bfri-20260113_def.xml EX-101.DEF 26983
6 XBRL LABEL FILE bfri-20260113_lab.xml EX-101.LAB 37209
7 XBRL PRESENTATION FILE bfri-20260113_pre.xml EX-101.PRE 25603
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6242
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 26528528
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)